# Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

> **NCT06232239** · PHASE1 · UNKNOWN · sponsor: **Bio-innova Co., Ltd** · enrollment: 26 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Empagliflozin-Test product
- **DRUG:** Empagliflozin-Reference product

## Key facts

- **NCT ID:** NCT06232239
- **Lead sponsor:** Bio-innova Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-27
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-19
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232239, "Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06232239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*